Latest Filings

Issuer Activity

Insider Overview :: Cardiome Pharma Corp. (T:COM) [?]
Business Focus: Biopharmaceuticals Share on StockTwits
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.
Log in or sign up for a free account to add this stock to your watch list.

Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for COM within the last 6 months [?]
Amended Filing
As of 11:59pm ET March 4th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jan 2/15 Dec 31/14 Lalji, Karim Fatehali Direct Ownership Common Shares 10 - Disposition in the public market -3,000 $10.69
Jan 2/15 Dec 30/14 Lalji, Karim Fatehali Direct Ownership Common Shares 10 - Disposition in the public market -1,400 $10.74
Jan 2/15 Dec 30/14 Lalji, Karim Fatehali Direct Ownership Common Shares 47 - Disposition by gift -28,600 $10.74
Jan 2/15 Dec 30/14 Lalji, Karim Fatehali Direct Ownership Options 52 - Expiration of options -11,112 $23.80
Jan 2/15 Dec 30/14 Grant, Sheila Direct Ownership Options 52 - Expiration of options -14,000 $23.80
Dec 24/14 Dec 24/14 Lalji, Karim Fatehali Direct Ownership Common Shares 51 - Exercise of options 30,000 $2.45
Dec 24/14 Dec 24/14 Lalji, Karim Fatehali Direct Ownership Options 51 - Exercise of options -30,000 $2.45
Dec 24/14 Dec 23/14 Lalji, Karim Fatehali Direct Ownership Common Shares 10 - Disposition in the public market -40,000 $10.19
Dec 24/14 Dec 23/14 Lalji, Karim Fatehali Direct Ownership Common Shares 51 - Exercise of options 40,000 $2.45
Dec 24/14 Dec 23/14 Lalji, Karim Fatehali Direct Ownership Options 51 - Exercise of options -40,000 $2.45
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for COM within the last 6 months [?]
Amended Filing
As of 11:59pm ET March 4th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jan 2/15 Dec 31/14 Lalji, Karim Fatehali Direct Ownership Common Shares 10 - Disposition in the public market -3,000 $10.69
Jan 2/15 Dec 30/14 Lalji, Karim Fatehali Direct Ownership Common Shares 10 - Disposition in the public market -1,400 $10.74
Jan 2/15 Dec 30/14 Lalji, Karim Fatehali Direct Ownership Common Shares 47 - Disposition by gift -28,600 $10.74
Jan 2/15 Dec 30/14 Lalji, Karim Fatehali Direct Ownership Options 52 - Expiration of options -11,112 $23.80
Jan 2/15 Dec 30/14 Grant, Sheila Direct Ownership Options 52 - Expiration of options -14,000 $23.80
Dec 24/14 Dec 24/14 Lalji, Karim Fatehali Direct Ownership Common Shares 51 - Exercise of options 30,000 $2.45
Dec 24/14 Dec 23/14 Lalji, Karim Fatehali Direct Ownership Common Shares 10 - Disposition in the public market -40,000 $10.19
Dec 24/14 Dec 23/14 Lalji, Karim Fatehali Direct Ownership Common Shares 51 - Exercise of options 40,000 $2.45
Dec 24/14 Dec 24/14 Lalji, Karim Fatehali Direct Ownership Options 51 - Exercise of options -30,000 $2.45
Dec 24/14 Dec 23/14 Lalji, Karim Fatehali Direct Ownership Options 51 - Exercise of options -40,000 $2.45
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for COM on March 4, 2015 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Key People
Robert W. Rieder
Chairman of the Board
William L. Hunter
President, Chief Executive Officer, Director
Jennifer Archibald
Chief Financial Officer
Sheila M. Grant
Chief Operating Officer
Karim Lalji
Chief Commercial Officer
 
Company Contact
Address: 6TH FLOOR, 6190 AGRONOMY RD.
VANCOUVER BC V6T 1Z3
Tel: N/A
Website: www.cardiome.com
IR: See website
Business Overview
Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company's clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral). In November 2013, Cardiome Pharma Corp. completed the acquisition of Correvio LLC.
Financial Overview
For the nine months ended 30 September 2014, Cardiome Pharma Corp. revenues increased from $644K to $23.1M. Net loss totaled $11.7M vs. income of $12M. Revenues reflect Product revenues increase from $81K to $20M, Revenue: Licensing fees increase from $563K to $3.1M. Net loss reflects Selling, general and administration increase from $9.2M to $24.7M (expense).
Employees: 75 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $186.96M as of Sep 30, 2014
Annual revenue (TTM): $33.46M as of Sep 30, 2014
EBITDA (TTM): -$16.02M as of Sep 30, 2014
Net annual income (TTM): -$23.57M as of Sep 30, 2014
Free cash flow (TTM): -$25.47M as of Sep 30, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 16,521,002 as of Oct 29, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
ProMetic Life Sciences (T:PLI)
Vanc Pharmaceuticals (V:NPH)
Transition Therapeutics (T:TTH)
 
Cardiome Pharma Corp. Insider Report Only $20.00